- About
- Mission Statement
Education. Evidence. Regrowth.
- Education.
Prioritize knowledge. Make better choices.
- Evidence.
Sort good studies from the bad.
- Regrowth.
Get bigger hair gains.
Team MembersPhD's, resarchers, & consumer advocates.
- Rob English
Founder, researcher, & consumer advocate
- Research Team
Our team of PhD’s, researchers, & more
Editorial PolicyDiscover how we conduct our research.
ContactHave questions? Contact us.
Before-Afters- Transformation Photos
Our library of before-after photos.
- — Jenna, 31, U.S.A.
I have attached my before and afters of my progress since joining this group...
- — Tom, 30, U.K.
I’m convinced I’ve recovered to probably the hairline I had 3 years ago. Super stoked…
- — Rabih, 30’s, U.S.A.
My friends actually told me, “Your hairline improved. Your hair looks thicker...
- — RDB, 35, New York, U.S.A.
I also feel my hair has a different texture to it now…
- — Aayush, 20’s, Boston, MA
Firstly thank you for your work in this field. I am immensely grateful that...
- — Ben M., U.S.A
I just wanted to thank you for all your research, for introducing me to this method...
- — Raul, 50, Spain
To be honest I am having fun with all this and I still don’t know how much...
- — Lisa, 52, U.S.
I see a massive amount of regrowth that is all less than about 8 cm long...
Client Testimonials150+ member experiences.
Scroll DownPopular Treatments- Treatments
Popular treatments. But do they work?
- Finasteride
- Oral
- Topical
- Dutasteride
- Oral
- Topical
- Mesotherapy
- Minoxidil
- Oral
- Topical
- Ketoconazole
- Shampoo
- Topical
- Low-Level Laser Therapy
- Therapy
- Microneedling
- Therapy
- Platelet-Rich Plasma Therapy (PRP)
- Therapy
- Scalp Massages
- Therapy
- More
IngredientsTop-selling ingredients, quantified.
- Saw Palmetto
- Redensyl
- Melatonin
- Caffeine
- Biotin
- Rosemary Oil
- Lilac Stem Cells
- Hydrolyzed Wheat Protein
- Sodium Lauryl Sulfate
- More
ProductsThe truth about hair loss "best sellers".
- Minoxidil Tablets
Xyon Health
- Finasteride
Strut Health
- Hair Growth Supplements
Happy Head
- REVITA Tablets for Hair Growth Support
DS Laboratories
- FoliGROWTH Ultimate Hair Neutraceutical
Advanced Trichology
- Enhance Hair Density Serum
Fully Vital
- Topical Finasteride and Minoxidil
Xyon Health
- HairOmega Foaming Hair Growth Serum
DrFormulas
- Bio-Cleansing Shampoo
Revivogen MD
- more
Key MetricsStandardized rubrics to evaluate all treatments.
- Evidence Quality
Is this treatment well studied?
- Regrowth Potential
How much regrowth can you expect?
- Long-Term Viability
Is this treatment safe & sustainable?
Free Research- Free Resources
Apps, tools, guides, freebies, & more.
- Free CalculatorTopical Finasteride Calculator
- Free Interactive GuideInteractive Guide: What Causes Hair Loss?
- Free ResourceFree Guide: Standardized Scalp Massages
- Free Course7-Day Hair Loss Email Course
- Free DatabaseIngredients Database
- Free Interactive GuideInteractive Guide: Hair Loss Disorders
- Free DatabaseTreatment Guides
- Free Lab TestsProduct Lab Tests: Purity & Potency
- Free Video & Write-upEvidence Quality Masterclass
- Free Interactive GuideDermatology Appointment Guide
- More
Articles100+ free articles.
-
Best Minoxidil for Women: Top 6 Brands of 2026
-
Best Minoxidil for Men: Top Picks for 2026
-
Switching From Finasteride to Dutasteride
-
Oral Minoxidil: Before and After Photos [2026]
-
Best Topical Finasteride: 5 Top Products of 2026
-
Oral Finasteride Before and After: Real Case Studies
-
Best Topical Dutasteride: 8 Choices for 2026
-
Does Finasteride Lower Testosterone?
PublicationsOur team’s peer-reviewed studies.
- Microneedling and Its Use in Hair Loss Disorders: A Systematic Review
- Use of Botulinum Toxin for Androgenic Alopecia: A Systematic Review
- Conflicting Reports Regarding the Histopathological Features of Androgenic Alopecia
- Self-Assessments of Standardized Scalp Massages for Androgenic Alopecia: Survey Results
- A Hypothetical Pathogenesis Model For Androgenic Alopecia:Clarifying The Dihydrotestosterone Paradox And Rate-Limiting Recovery Factors
Menu- AboutAbout
- Mission Statement
Education. Evidence. Regrowth.
- Team Members
PhD's, resarchers, & consumer advocates.
- Editorial Policy
Discover how we conduct our research.
- Contact
Have questions? Contact us.
- Before-Afters
Before-Afters- Transformation Photos
Our library of before-after photos.
- Client Testimonials
Read the experiences of members
Before-Afters/ Client Testimonials- Popular Treatments
-
Treatments-
Oral
-
Topical
-
Mesotherapy
-
Oral Finasteride
By Rob EnglishMedically Reviewed by Rob EnglishFirst Published Sep 13, 2023Last Updated Sep 13, 2023
Evidence Quality
Regrowth Potential
Long-Term Viability
Key Information
Free Resources
KEY INFORMATIONWhat is it?
What is it?
What is it?
What is it?
What is it?
What is it?
FREE RESOURCESResearch Tables
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean scelerisque, nulla ut vulputate pretium, sapien velit volutpat ipsum, non mattis dui nulla tempus eros.
Results
Search Criteria
Parameter
Inclusion Criteria
Exclusion Criteria
Patients Patients of any age with hair loss Patients with no hair loss disorder. Intervention Oral finasteride as a standalone or adjunct therapy. A study that doesn’t contain oral finasteride either as a standalone or adjunct therapy Comparator Placebo and/or other therapies or baseline. No comparator. Outcomes No comparator.Primary Endpoints of phototrichogram, investigator, and/or patient assessments. Any study not designed to adequately test for the standalone or additive effect of oral finasteride. Study Design Prospective, randomized controlled trials Literature reviews, non-human subjects, or ongoing clinical trials. Search Terms
Search Terms:
FINASTERIDE ORAL HAIR LOSS ALOPECIA-
Abbreviations:
-
AGAAndrogenetic Alopecia
-
GPAGlobal Photographic Assessment
-
FPHLFemale pattern hair loss
-
MPHLMale pattern hair loss
Summarized Studies
Study Participants Design Treatment Results Key Takeaway Adverse Effects EQ Authors (year) Sex Hair Loss Type Design Dose Usage Duration Endpoints Hair Growth Assessments Summary Limitations Adverse Effects Jadad Score Liang et al. (2023) n=120(F) Group 1: 40 Group 2: 40 Group 3: 40 FPHL
Prospective, single-center, parallel-group, evaluator-blinded, randomized trial Group 1: 5% MXT Group 2: 5% MX + 80-100 mg SPT Group 3: 5% topical MX + MN Group 1: Once daily. Group 2: Once daily. Group 3: MXT once daily, alongside MN every 2 weeks. 24 weeks Dermascope evaluation, ultrasound biomicroscopy (UBM), physician's global assessment, and patient assessment. Group 1: showed improvement at week 24 in hair density and shaft diameter. The effective rate was 55.27% at week 24. Group 2: The effective rate was 86.49% at week 24. Group 3: The effective rate was 95% at week 24. The degree of improvement of hair density at week 24 in Group 1 was less than in the latter two. The combined therapies showed advantages in efficacy over 5% MXT alone. Group 3 showed significant improvement in most endpoints, including hair density, hair shaft, diameter, epidermal thickness, dermis thickness, follicle diameter, hair shedding score, and QoL score Small sample size, exclusion of severe FPHL patients, and potential bias from unblinded treatments among the 3 groups. Group 1: Facial hypertrichosis (n=4), trichomadesis aggravating (n=4), scalp pruritus (n=8), increased scurf (n=7), headache (n=1), palpitation (n=1), postural hypotension (n=1), urticaria (n=1). Group 2: facial hypertrichosis (n=5), trichomadesis aggravating (n=4), scalp pruritus (n=8), increased scurf (n=6), edema (n=1), headache (n=1), palpitation (n=3), hyperkalemia (n=1), menstrual disorder (n=15), urticaria (n=1) 4Liang et al. (2023) n=120(F) Group 1: 40 Group 2: 40 Group 3: 40 FPHL
Prospective, single-center, parallel-group, evaluator-blinded, randomized trial Group 1: 5% MXT Group 2: 5% MX + 80-100 mg SPT Group 3: 5% topical MX + MN Group 1: Once daily. Group 2: Once daily. Group 3: MXT once daily, alongside MN every 2 weeks. 24 weeks Dermascope evaluation, ultrasound biomicroscopy (UBM), physician's global assessment, and patient assessment. Group 1: showed improvement at week 24 in hair density and shaft diameter. The effective rate was 55.27% at week 24. Group 2: The effective rate was 86.49% at week 24. Group 3: The effective rate was 95% at week 24. The degree of improvement of hair density at week 24 in Group 1 was less than in the latter two. The combined therapies showed advantages in efficacy over 5% MXT alone. Group 3 showed significant improvement in most endpoints, including hair density, hair shaft, diameter, epidermal thickness, dermis thickness, follicle diameter, hair shedding score, and QoL score Small sample size, exclusion of severe FPHL patients, and potential bias from unblinded treatments among the 3 groups. Group 1: Facial hypertrichosis (n=4), trichomadesis aggravating (n=4), scalp pruritus (n=8), increased scurf (n=7), headache (n=1), palpitation (n=1), postural hypotension (n=1), urticaria (n=1). Group 2: facial hypertrichosis (n=5), trichomadesis aggravating (n=4), scalp pruritus (n=8), increased scurf (n=6), edema (n=1), headache (n=1), palpitation (n=3), hyperkalemia (n=1), menstrual disorder (n=15), urticaria (n=1) 4FREE RESOURCESArticles
Explore the science behind hair loss and hair growth. Our in-depth articles cover topics ranging from natural remedies to pharmaceuticals to breakthroughs in hair loss science. Want to request an article topic? Contact us.
Product Reviews
By Rob EnglishSep 13, 2023Leave CommentHMI-115: What We Know So Far
HMI-115 lowers prolactin levels and is currently in clinical trials for the treatment of androgenic alopecia (AGA). Internal, non-peer-reviewed research suggests that HMI-115 may promote hair regrowth in monkeys. Anecdotes from its phase I trials in humans imply that HMI-115 may also regrow hair in men with AGA. But is this the whole story? In …
Product Reviews
By Rob EnglishSep 13, 2023Leave CommentHMI-115: What We Know So Far
HMI-115 lowers prolactin levels and is currently in clinical trials for the treatment of androgenic alopecia (AGA). Internal, non-peer-reviewed research suggests that HMI-115 may promote hair regrowth in monkeys. Anecdotes from its phase I trials in humans imply that HMI-115 may also regrow hair in men with AGA. But is this the whole story? In …
Product Reviews
By Rob EnglishSep 13, 2023Leave CommentHMI-115: What We Know So Far
HMI-115 lowers prolactin levels and is currently in clinical trials for the treatment of androgenic alopecia (AGA). Internal, non-peer-reviewed research suggests that HMI-115 may promote hair regrowth in monkeys. Anecdotes from its phase I trials in humans imply that HMI-115 may also regrow hair in men with AGA. But is this the whole story? In …
Product Reviews
By Rob EnglishSep 13, 2023Leave CommentHMI-115: What We Know So Far
HMI-115 lowers prolactin levels and is currently in clinical trials for the treatment of androgenic alopecia (AGA). Internal, non-peer-reviewed research suggests that HMI-115 may promote hair regrowth in monkeys. Anecdotes from its phase I trials in humans imply that HMI-115 may also regrow hair in men with AGA. But is this the whole story? In …
Product Reviews
By Rob EnglishSep 13, 2023Leave CommentHMI-115: What We Know So Far
eviewed research suggests that HMI-115 may promote hair regrowth in monkeys. Anecdotes from its phase I trials in humans imply that HMI-115 may also regrow hair in men with AGA. But is this the whole story? In …
More
-
-
Oral Finasteride
By Rob EnglishMedically Reviewed by Rob EnglishFirst Published Sep 13, 2023Last Updated Sep 13, 2023
Evidence Quality
Regrowth Potential
Long-Term Viability
Key Information
Free Resources
KEY INFORMATIONWhat is it?
What is it?
What is it?
What is it?
What is it?
What is it?
FREE RESOURCESResearch Tables
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean scelerisque, nulla ut vulputate pretium, sapien velit volutpat ipsum, non mattis dui nulla tempus eros.
Results
Search Criteria
Parameter
Inclusion Criteria
Exclusion Criteria
Patients Patients of any age with hair loss Patients with no hair loss disorder. Intervention Oral finasteride as a standalone or adjunct therapy. A study that doesn’t contain oral finasteride either as a standalone or adjunct therapy Comparator Placebo and/or other therapies or baseline. No comparator. Outcomes No comparator.Primary Endpoints of phototrichogram, investigator, and/or patient assessments. Any study not designed to adequately test for the standalone or additive effect of oral finasteride. Study Design Prospective, randomized controlled trials Literature reviews, non-human subjects, or ongoing clinical trials. Search Terms
Search Terms:
FINASTERIDE ORAL HAIR LOSS ALOPECIA-
Abbreviations:
-
AGAAndrogenetic Alopecia
-
GPAGlobal Photographic Assessment
-
FPHLFemale pattern hair loss
-
MPHLMale pattern hair loss
Summarized Studies
Study Participants Design Treatment Results Key Takeaway Adverse Effects EQ Authors (year) Sex Hair Loss Type Design Dose Usage Duration Endpoints Hair Growth Assessments Summary Limitations Adverse Effects Jadad Score Liang et al. (2023) n=120(F) Group 1: 40 Group 2: 40 Group 3: 40 FPHL
Prospective, single-center, parallel-group, evaluator-blinded, randomized trial Group 1: 5% MXT Group 2: 5% MX + 80-100 mg SPT Group 3: 5% topical MX + MN Group 1: Once daily. Group 2: Once daily. Group 3: MXT once daily, alongside MN every 2 weeks. 24 weeks Dermascope evaluation, ultrasound biomicroscopy (UBM), physician's global assessment, and patient assessment. Group 1: showed improvement at week 24 in hair density and shaft diameter. The effective rate was 55.27% at week 24. Group 2: The effective rate was 86.49% at week 24. Group 3: The effective rate was 95% at week 24. The degree of improvement of hair density at week 24 in Group 1 was less than in the latter two. The combined therapies showed advantages in efficacy over 5% MXT alone. Group 3 showed significant improvement in most endpoints, including hair density, hair shaft, diameter, epidermal thickness, dermis thickness, follicle diameter, hair shedding score, and QoL score Small sample size, exclusion of severe FPHL patients, and potential bias from unblinded treatments among the 3 groups. Group 1: Facial hypertrichosis (n=4), trichomadesis aggravating (n=4), scalp pruritus (n=8), increased scurf (n=7), headache (n=1), palpitation (n=1), postural hypotension (n=1), urticaria (n=1). Group 2: facial hypertrichosis (n=5), trichomadesis aggravating (n=4), scalp pruritus (n=8), increased scurf (n=6), edema (n=1), headache (n=1), palpitation (n=3), hyperkalemia (n=1), menstrual disorder (n=15), urticaria (n=1) 4Liang et al. (2023) n=120(F) Group 1: 40 Group 2: 40 Group 3: 40 FPHL
Prospective, single-center, parallel-group, evaluator-blinded, randomized trial Group 1: 5% MXT Group 2: 5% MX + 80-100 mg SPT Group 3: 5% topical MX + MN Group 1: Once daily. Group 2: Once daily. Group 3: MXT once daily, alongside MN every 2 weeks. 24 weeks Dermascope evaluation, ultrasound biomicroscopy (UBM), physician's global assessment, and patient assessment. Group 1: showed improvement at week 24 in hair density and shaft diameter. The effective rate was 55.27% at week 24. Group 2: The effective rate was 86.49% at week 24. Group 3: The effective rate was 95% at week 24. The degree of improvement of hair density at week 24 in Group 1 was less than in the latter two. The combined therapies showed advantages in efficacy over 5% MXT alone. Group 3 showed significant improvement in most endpoints, including hair density, hair shaft, diameter, epidermal thickness, dermis thickness, follicle diameter, hair shedding score, and QoL score Small sample size, exclusion of severe FPHL patients, and potential bias from unblinded treatments among the 3 groups. Group 1: Facial hypertrichosis (n=4), trichomadesis aggravating (n=4), scalp pruritus (n=8), increased scurf (n=7), headache (n=1), palpitation (n=1), postural hypotension (n=1), urticaria (n=1). Group 2: facial hypertrichosis (n=5), trichomadesis aggravating (n=4), scalp pruritus (n=8), increased scurf (n=6), edema (n=1), headache (n=1), palpitation (n=3), hyperkalemia (n=1), menstrual disorder (n=15), urticaria (n=1) 4FREE RESOURCESArticles
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean scelerisque, nulla ut vulputate pretium, sapien velit volutpat ipsum, non mattis dui nulla tempus eros.
Product Reviews
By Rob EnglishSep 13, 2023Leave CommentHMI-115: What We Know So Far
HMI-115 lowers prolactin levels and is currently in clinical trials for the treatment of androgenic alopecia (AGA). Internal, non-peer-reviewed research suggests that HMI-115 may promote hair regrowth in monkeys. Anecdotes from its phase I trials in humans imply that HMI-115 may also regrow hair in men with AGA. But is this the whole story? In …
Product Reviews
By Rob EnglishSep 13, 2023Leave CommentHMI-115: What We Know So Far
HMI-115 lowers prolactin levels and is currently in clinical trials for the treatment of androgenic alopecia (AGA). Internal, non-peer-reviewed research suggests that HMI-115 may promote hair regrowth in monkeys. Anecdotes from its phase I trials in humans imply that HMI-115 may also regrow hair in men with AGA. But is this the whole story? In …
Product Reviews
By Rob EnglishSep 13, 2023Leave CommentHMI-115: What We Know So Far
HMI-115 lowers prolactin levels and is currently in clinical trials for the treatment of androgenic alopecia (AGA). Internal, non-peer-reviewed research suggests that HMI-115 may promote hair regrowth in monkeys. Anecdotes from its phase I trials in humans imply that HMI-115 may also regrow hair in men with AGA. But is this the whole story? In …
Product Reviews
By Rob EnglishSep 13, 2023Leave CommentHMI-115: What We Know So Far
HMI-115 lowers prolactin levels and is currently in clinical trials for the treatment of androgenic alopecia (AGA). Internal, non-peer-reviewed research suggests that HMI-115 may promote hair regrowth in monkeys. Anecdotes from its phase I trials in humans imply that HMI-115 may also regrow hair in men with AGA. But is this the whole story? In …
Product Reviews
By Rob EnglishSep 13, 2023Leave CommentHMI-115: What We Know So Far
eviewed research suggests that HMI-115 may promote hair regrowth in monkeys. Anecdotes from its phase I trials in humans imply that HMI-115 may also regrow hair in men with AGA. But is this the whole story? In …
More
-
-
Oral Finasteride
By Rob EnglishMedically Reviewed by Rob EnglishFirst Published Sep 13, 2023Last Updated Sep 13, 2023
Evidence Quality
Regrowth Potential
Long-Term Viability
Key Information
Free Resources
KEY INFORMATIONWhat is it?
What is it?
What is it?
What is it?
What is it?
What is it?
FREE RESOURCESResearch Tables
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean scelerisque, nulla ut vulputate pretium, sapien velit volutpat ipsum, non mattis dui nulla tempus eros.
Results
Search Criteria
Parameter
Inclusion Criteria
Exclusion Criteria
Patients Patients of any age with hair loss Patients with no hair loss disorder. Intervention Oral finasteride as a standalone or adjunct therapy. A study that doesn’t contain oral finasteride either as a standalone or adjunct therapy Comparator Placebo and/or other therapies or baseline. No comparator. Outcomes No comparator.Primary Endpoints of phototrichogram, investigator, and/or patient assessments. Any study not designed to adequately test for the standalone or additive effect of oral finasteride. Study Design Prospective, randomized controlled trials Literature reviews, non-human subjects, or ongoing clinical trials. Search Terms
Search Terms:
FINASTERIDE ORAL HAIR LOSS ALOPECIA-
Abbreviations:
-
AGAAndrogenetic Alopecia
-
GPAGlobal Photographic Assessment
-
FPHLFemale pattern hair loss
-
MPHLMale pattern hair loss
Summarized Studies
Study Participants Design Treatment Results Key Takeaway Adverse Effects EQ Authors (year) Sex Hair Loss Type Design Dose Usage Duration Endpoints Hair Growth Assessments Summary Limitations Adverse Effects Jadad Score Liang et al. (2023) n=120(F) Group 1: 40 Group 2: 40 Group 3: 40 FPHL
Prospective, single-center, parallel-group, evaluator-blinded, randomized trial Group 1: 5% MXT Group 2: 5% MX + 80-100 mg SPT Group 3: 5% topical MX + MN Group 1: Once daily. Group 2: Once daily. Group 3: MXT once daily, alongside MN every 2 weeks. 24 weeks Dermascope evaluation, ultrasound biomicroscopy (UBM), physician's global assessment, and patient assessment. Group 1: showed improvement at week 24 in hair density and shaft diameter. The effective rate was 55.27% at week 24. Group 2: The effective rate was 86.49% at week 24. Group 3: The effective rate was 95% at week 24. The degree of improvement of hair density at week 24 in Group 1 was less than in the latter two. The combined therapies showed advantages in efficacy over 5% MXT alone. Group 3 showed significant improvement in most endpoints, including hair density, hair shaft, diameter, epidermal thickness, dermis thickness, follicle diameter, hair shedding score, and QoL score Small sample size, exclusion of severe FPHL patients, and potential bias from unblinded treatments among the 3 groups. Group 1: Facial hypertrichosis (n=4), trichomadesis aggravating (n=4), scalp pruritus (n=8), increased scurf (n=7), headache (n=1), palpitation (n=1), postural hypotension (n=1), urticaria (n=1). Group 2: facial hypertrichosis (n=5), trichomadesis aggravating (n=4), scalp pruritus (n=8), increased scurf (n=6), edema (n=1), headache (n=1), palpitation (n=3), hyperkalemia (n=1), menstrual disorder (n=15), urticaria (n=1) 4Liang et al. (2023) n=120(F) Group 1: 40 Group 2: 40 Group 3: 40 FPHL
Prospective, single-center, parallel-group, evaluator-blinded, randomized trial Group 1: 5% MXT Group 2: 5% MX + 80-100 mg SPT Group 3: 5% topical MX + MN Group 1: Once daily. Group 2: Once daily. Group 3: MXT once daily, alongside MN every 2 weeks. 24 weeks Dermascope evaluation, ultrasound biomicroscopy (UBM), physician's global assessment, and patient assessment. Group 1: showed improvement at week 24 in hair density and shaft diameter. The effective rate was 55.27% at week 24. Group 2: The effective rate was 86.49% at week 24. Group 3: The effective rate was 95% at week 24. The degree of improvement of hair density at week 24 in Group 1 was less than in the latter two. The combined therapies showed advantages in efficacy over 5% MXT alone. Group 3 showed significant improvement in most endpoints, including hair density, hair shaft, diameter, epidermal thickness, dermis thickness, follicle diameter, hair shedding score, and QoL score Small sample size, exclusion of severe FPHL patients, and potential bias from unblinded treatments among the 3 groups. Group 1: Facial hypertrichosis (n=4), trichomadesis aggravating (n=4), scalp pruritus (n=8), increased scurf (n=7), headache (n=1), palpitation (n=1), postural hypotension (n=1), urticaria (n=1). Group 2: facial hypertrichosis (n=5), trichomadesis aggravating (n=4), scalp pruritus (n=8), increased scurf (n=6), edema (n=1), headache (n=1), palpitation (n=3), hyperkalemia (n=1), menstrual disorder (n=15), urticaria (n=1) 4FREE RESOURCESArticles
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean scelerisque, nulla ut vulputate pretium, sapien velit volutpat ipsum, non mattis dui nulla tempus eros.
Product Reviews
By Rob EnglishSep 13, 2023Leave CommentHMI-115: What We Know So Far
HMI-115 lowers prolactin levels and is currently in clinical trials for the treatment of androgenic alopecia (AGA). Internal, non-peer-reviewed research suggests that HMI-115 may promote hair regrowth in monkeys. Anecdotes from its phase I trials in humans imply that HMI-115 may also regrow hair in men with AGA. But is this the whole story? In …
Product Reviews
By Rob EnglishSep 13, 2023Leave CommentHMI-115: What We Know So Far
HMI-115 lowers prolactin levels and is currently in clinical trials for the treatment of androgenic alopecia (AGA). Internal, non-peer-reviewed research suggests that HMI-115 may promote hair regrowth in monkeys. Anecdotes from its phase I trials in humans imply that HMI-115 may also regrow hair in men with AGA. But is this the whole story? In …
Product Reviews
By Rob EnglishSep 13, 2023Leave CommentHMI-115: What We Know So Far
HMI-115 lowers prolactin levels and is currently in clinical trials for the treatment of androgenic alopecia (AGA). Internal, non-peer-reviewed research suggests that HMI-115 may promote hair regrowth in monkeys. Anecdotes from its phase I trials in humans imply that HMI-115 may also regrow hair in men with AGA. But is this the whole story? In …
Product Reviews
By Rob EnglishSep 13, 2023Leave CommentHMI-115: What We Know So Far
HMI-115 lowers prolactin levels and is currently in clinical trials for the treatment of androgenic alopecia (AGA). Internal, non-peer-reviewed research suggests that HMI-115 may promote hair regrowth in monkeys. Anecdotes from its phase I trials in humans imply that HMI-115 may also regrow hair in men with AGA. But is this the whole story? In …
Product Reviews
By Rob EnglishSep 13, 2023Leave CommentHMI-115: What We Know So Far
eviewed research suggests that HMI-115 may promote hair regrowth in monkeys. Anecdotes from its phase I trials in humans imply that HMI-115 may also regrow hair in men with AGA. But is this the whole story? In …
More
-
- Mission Statement
Scroll Down
More
More